glp 1 and antipsychotics Antipsychotic Weight Gain Metabolic Syndrome (MetS) Impacts of Glucagon-like Peptide-1 Receptor-Agonist

Can non-diabetics take GLP-1

Attenuation of stress-induced gastrointestinal motility disorder by gentiopicroside, from gentiana macrophylla pall

Finally, we highlight emerging therapeutic strategies targeting these pathways and discuss how leveraging multiomics advances can translate lipid insights into cancer immunotherapy

A 2022 study published in Diabetes, Obesity and Metabolism found that adults over 50 achieved clinically significant weight loss on semaglutide, with cardiovascular and metabolic risk reductions comparable to younger cohorts, though the authors noted the importance of individualized monitoring protocols for older patients given the higher baseline prevalence of comorbidities

HR: 0.62, 95% CI: 0.460.84)